Released on September 01, 2016

Approximately 600,000 new cases of head and neck cancer (HNC) would be diagnosed worldwide this year.  Of those, a bit less than 10% would occur in the United States.  Most of these neoplasms would be histologically diagnosed as a squamous cell carcinomas for which the preferred treatment...

Released on December 10, 2016

Dusquetide, a novel Innate Defense Regulator, modulates the innate immune system at a key convergence point in intracellular signaling pathways and has demonstrated activity in both reducing inflammation and increasing clearance of bacterial infection.  Innate immunity has also been implicated...

Released on January 13, 2017

Objective: mTOR inhibitor treatment of solid cancers is associated with mTOR inhibitor-associated stomatitis (mIAS) a common, significant, dose-limiting toxicity, with aphthous-like lesions.  Our objective was to assess the utility of a new organotypic model in defining mIAS’ pathogenesis....

Released on April 01, 2017

Oral mucositis remains one of the most dominant, serious, disruptive, and symptomatic complications of radiation therapy used for the treatment of cancers of the head and neck (Villa and Sonis, 2015).  Progressive mucosal injury accompanies increasing daily radiation fractions until confluent...

Released on June 08, 2017

Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents.  It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment.  Moreover, the economic impact related to the management of...

Released on May 17, 2017

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT).  Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM).  Long term...

Released on August 08, 2017

Context: Despite numerous proposed mechanisms, no definitive pathophysiology underlying radiotherapy-induced fatigue (RIF) has been established.  However, the dysregulation of a set of 35 genes was recently validated to predict development of fatigue in prostate cancer patients receiving...

Released on April 01, 2013

Aphthous-like stomatitis has been identified as one of the most common dose-limiting toxicities associated with mTOR inhibitor therapy in cancer patients. The objective of this study was to summarize the cumulative oral toxicities associated with mTOR inhibitors in published oncology trials with...

Released on August 01, 2013

Objective: We report the clinical features and management outcomes in 7 patients with everolimus-related stomatitis. Study Design: Fifteen women with hormone-receptor-positive advanced breast cancer receiving everolimus combined with exemestane were prospectively evaluated to assess the...

Released on July 01, 2013

Background: Considerable progress has been made in our understanding of the biological basis for cancer therapy-induced mucosal barrier injury (mucositis). The last formal review of the subject by MASCC/ISOO was published in 2007; consequently, an update is timely. Methods: Panel members reviewed...